List of Tegsedi drug patents
Tegsedi is owned by Akcea Theraps.
Tegsedi contains Inotersen Sodium.
Tegsedi has a total of 6 drug patents out of which 0 drug patents have expired.
Tegsedi was authorised for market use on 05 October, 2018.
Tegsedi is available in solution;subcutaneous dosage forms.
Tegsedi can be used as treatment of polyneuropathy of hereditary transthyretin amyloidosis.
Drug patent challenges can be filed against Tegsedi from October, 2022.
The generics of Tegsedi are possible to be released after 29 April, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7015315 | AKCEA THERAPS | Gapped oligonucleotides |
Mar, 2023
(a month from now) | |
| US7101993 | AKCEA THERAPS | Oligonucleotides containing 2′-O-modified purines |
Sep, 2023
(6 months from now) | |
| US8101743 | AKCEA THERAPS | Modulation of transthyretin expression |
Apr, 2025
(2 years from now) | |
| US9061044 | AKCEA THERAPS | Modulation of transthyretin expression |
Apr, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9399774 | AKCEA THERAPS | Modulation of transthyretin expression |
Apr, 2031
(8 years from now) | |
| US8697860 | AKCEA THERAPS | Diagnosis and treatment of disease |
Apr, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 5, 2023 |
| Orphan Drug Exclusivity (ODE) | Oct 5, 2025 |
Drugs and Companies using INOTERSEN SODIUM ingredient
NCE-1 date: October, 2022
Market Authorisation Date: 05 October, 2018
Treatment: Treatment of polyneuropathy of hereditary transthyretin amyloidosis
Dosage: SOLUTION;SUBCUTANEOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic